Compounds > marimastat
Page last updated: 2024-09-03

marimastat and Local Neoplasm Recurrence

marimastat has been researched along with Local Neoplasm Recurrence in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (75.00)29.6817
2010's1 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Antonarakis, ES; Lin, J; Suzman, DL; Zahurak, ML; Zhou, XC1
Carducci, MA; DeWeese, TL; Eisenberger, MA; Laufer, M; Pili, R; Rosenbaum, E; Sinibaldi, V; Zahurak, M1
Aldape, KD; Conrad, CA; Gilbert, MR; Groves, MD; Hess, KR; Jaeckle, K; Levin, VA; Liu, V; Puduvalli, VK; Yung, WK1
Groves, MD; Hess, KR; Jaeckle, KA; Levin, VA; Peterson, P; Puduvalli, VK; Yung, WK1

Trials

4 trial(s) available for marimastat and Local Neoplasm Recurrence

ArticleYear
Change in PSA velocity is a predictor of overall survival in men with biochemically-recurrent prostate cancer treated with nonhormonal agents: combined analysis of four phase-2 trials.
    Prostate cancer and prostatic diseases, 2015, Volume: 18, Issue:1

    Topics: Aged; Benzamides; Biomarkers; Biomarkers, Tumor; Disease-Free Survival; Humans; Hydroxamic Acids; Imatinib Mesylate; Kinetics; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Piperazines; Prognosis; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Pyrimidines

2015
Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trial.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Jun-15, Volume: 11, Issue:12

    Topics: Aged; Analysis of Variance; Arthralgia; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Humans; Hydroxamic Acids; Male; Metalloendopeptidases; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Time; Treatment Outcome

2005
Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status.
    Journal of neuro-oncology, 2006, Volume: 80, Issue:1

    Topics: Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytochrome P-450 Enzyme System; Dacarbazine; Disease-Free Survival; Enzyme Inhibitors; Glioma; Humans; Hydroxamic Acids; Joint Diseases; Joints; Neoplasm Recurrence, Local; Survival Analysis; Temozolomide; Treatment Outcome

2006
Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Mar-01, Volume: 20, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Enzyme Inhibitors; Female; Glioblastoma; Humans; Hydroxamic Acids; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide

2002